Amgen delivered robust first-quarter results, showcasing significant revenue and earnings growth while raising its full-year guidance. The successful launches of new products, strategic pipeline advancements, and increased shareholder returns through dividends and buybacks indicate strong operational performance and investor confidence. These positive developments are likely to foster a favorable short-term impact on the stock.

[1]